Monoclonal Antibody BCMab1 Targets Aberrant Integrin for Bladder Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer, such as chemotherapeutic agents and immunopotentiators, suffer from low specificity, drug resistance, and significant side effects, and existing diagnostic methods for bladder cancer have limitations in sensitivity and specificity, making early detection and effective prevention of relapse challenging.
Innovation Solution
Development of a monoclonal antibody BCMab1 that specifically targets aberrantly glycosylated integrin α3β1, which is expressed only on bladder tumor cells, and its use in a competitive ELISA method for detecting bladder cancer in urine, along with the creation of an immunotoxin BCMab1-Ra for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents and immunopotentiators are used for bladder cancer treatment, then some therapeutic effect is achieved, but specificity is low and side effects are significant
Solution Approach 1:
The invention segments the treatment approach by identifying and targeting a specific molecular marker (aberrantly glycosylated integrin α3β1) that is uniquely expressed on bladder tumor cells. This segmentation allows the therapeutic agent to distinguish between cancerous and normal cells, thereby improving specificity and reducing side effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention applies local quality by creating a treatment that specifically targets the aberrant glycosylation pattern found only on bladder tumor cells. The monoclonal antibody is designed to recognize and bind to this localized molecular characteristic, enabling precise delivery of therapeutic effect to the tumor site while leaving surrounding healthy tissues unaffected.
2Reliability
If conventional diagnostic methods are used for bladder cancer detection, then diagnosis is achieved, but sensitivity and specificity are limited
Solution Approach 1:
The invention employs preliminary action by using the monoclonal antibody to detect and isolate aberrantly glycosylated integrin α3β1 from urine samples before final diagnosis. This preliminary detection step enables early identification of bladder cancer markers, improving both sensitivity for early detection and specificity by targeting a molecule unique to bladder tumor cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BCMab1 effectively inhibits bladder cancer cell proliferation and is highly specific for bladder cancer cells, offering a promising diagnostic and therapeutic approach with reduced side effects and improved sensitivity and specificity compared to existing methods.
Implementation Method 1
the antibody BCMab1 not only specifically recognizes AG-α3β1, but also effectively inhibits the proliferation of human bladder tumor cells
Implementation Method 2
a process for detecting bladder cancer in human using a competitive ELISA. In such a detecting process, the antigen in an immobile phase is human bladder cancer tumor marker AG-α3β1 according to the present invention, and the detection antibody is the antibody BCMab1 directed against human bladder cancer integrin α3β1
Data Source
AI summary
Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.